Pandak W M, Heuman D M, Hylemon P B, Vlahcevic Z R
Department of Medicine, Medical College of Virginia, Richmond 23298.
J Lipid Res. 1990 Jan;31(1):79-90.
Under most experimental conditions, the activities of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA reductase) and cholesterol 7 alpha-hydroxylase, change together in parallel directions. It has been suggested that newly synthesized cholesterol may be the preferred substrate for cholesterol 7 alpha-hydroxylase, which may account for the observed synchronous behavior of the two enzymes. To test this hypothesis, mevinolinic acid, a potent competitive inhibitor of HMG-CoA reductase, was administered as a single intravenous bolus (10 mg/kg) to rats with a chronic bile fistula. Bile acid synthesis was determined following inhibition of HMG-CoA reductase by mevinolinic acid over a 27-h time course and specific activities of HMG-CoA reductase and cholesterol 7 alpha-hydroxylase were determined in liver microsomes. At 3, 6, and 27 h after a bolus dose of mevinolinic acid, bile acid synthesis was reduced by 54 +/- 5%, 42 +/- 8%, and 23 +/- 13%, respectively, from preinfusion baseline. Within 30 min after administration of mevinolinic acid, HMG-CoA reductase activity was inhibited by at least 87%. At 0.5, 1.5, 3, 6, and 27 h after mevinolinic acid injection, cholesterol 7 alpha-hydroxylase activity was decreased by 6%, 25%, 54%, 41%, and 17%, respectively. By 27 h, the activities of both enzymes had returned to baseline levels. The reduction of bile acid synthesis correlated closely with the observed changes in the activities of cholesterol 7 alpha-hydroxylase. In vitro addition of mevinolinic acid (up to 20 microM) to rat liver microsomes failed to inhibit cholesterol 7 alpha-hydroxylase activity, suggesting no direct effect of mevinolinic acid on enzyme activity. When a bolus dose of mevinolinic acid was coupled with a continuous infusion of mevalonate, the product of the reaction catalyzed by HMG-CoA reductase, the mevinolinic acid-induced decrease in cholesterol 7 alpha-hydroxylase activity and bile acid synthesis was prevented. The results of this study provide evidence that, under the experimental conditions described, there is a linkage between the rates of cholesterol synthesis and the activities of cholesterol 7 alpha-hydroxylase. The data also emphasize the importance of the newly synthesized cholesterol in the regulation of cholesterol 7 alpha-hydroxylase activity.
在大多数实验条件下,3-羟基-3-甲基戊二酰辅酶A(HMG-CoA还原酶)和胆固醇7α-羟化酶的活性呈平行方向共同变化。有人提出,新合成的胆固醇可能是胆固醇7α-羟化酶的首选底物,这可能解释了两种酶观察到的同步行为。为了验证这一假设,将洛伐他汀酸(一种强效的HMG-CoA还原酶竞争性抑制剂)以单次静脉推注(10mg/kg)的方式给予患有慢性胆瘘的大鼠。在27小时的时间进程中,测定洛伐他汀酸抑制HMG-CoA还原酶后胆汁酸的合成,并测定肝微粒体中HMG-CoA还原酶和胆固醇7α-羟化酶的比活性。在推注洛伐他汀酸后的3小时、6小时和27小时,胆汁酸合成分别比输注前基线降低了54±5%、42±8%和23±13%。在给予洛伐他汀酸后30分钟内,HMG-CoA还原酶活性至少被抑制87%。在注射洛伐他汀酸后的0.5小时、1.5小时、3小时、6小时和27小时,胆固醇7α-羟化酶活性分别降低了6%、25%、54%、41%和17%。到27小时时,两种酶的活性均恢复到基线水平。胆汁酸合成的减少与胆固醇7α-羟化酶活性的观察变化密切相关。在大鼠肝微粒体中体外添加洛伐他汀酸(高达20μM)未能抑制胆固醇7α-羟化酶活性,表明洛伐他汀酸对酶活性无直接影响。当推注剂量的洛伐他汀酸与甲羟戊酸(HMG-CoA还原酶催化反应的产物)持续输注相结合时,洛伐他汀酸诱导的胆固醇7α-羟化酶活性降低和胆汁酸合成减少被阻止。本研究结果提供了证据,表明在所描述的实验条件下,胆固醇合成速率与胆固醇7α-羟化酶活性之间存在联系。数据还强调了新合成的胆固醇在调节胆固醇7α-羟化酶活性中的重要性。